cognitive impairment
05/02/2017
/
By Amy Goodrich
Dangerous Alzheimer’s treatment drug DONEPEZIL being widely prescribed “off-label” was never approved for such uses by the FDA
Donepezil is an acetylcholinesterase inhibitor approved by the Food and Drug Administration (FDA) in the United States to treat Alzheimer’s disease. Since mild cognitive impairment (MCI), or the phase between normal age-related brain decline and dementia, displays similar symptoms to Alzheimer’s, many physicians also prescribe this drug off-label to patients with MCI. Researchers from the […]
« Return Home
1 of 1
Popular Articles
COPYRIGHT © 2017 BIG PHARMA NEWS
Privacy Policy
